# LFMT vs Placebo in New Biologic Start for Ulcerative Colitis

> **NCT05327790** · PHASE2 · RECRUITING · sponsor: **University of Alberta** · enrollment: 40 (estimated)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Lyophilized fecal microbiota (LFMT)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05327790
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-03
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05327790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05327790, "LFMT vs Placebo in New Biologic Start for Ulcerative Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05327790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*